Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma - PubMed (original) (raw)
. 2021 May 15;27(10):2868-2878.
doi: 10.1158/1078-0432.CCR-20-4119. Epub 2021 Mar 15.
Affiliations
- PMID: 33722896
- DOI: 10.1158/1078-0432.CCR-20-4119
Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma
Eliana Marostica et al. Clin Cancer Res. 2021.
Abstract
Purpose: Histopathology evaluation is the gold standard for diagnosing clear cell (ccRCC), papillary, and chromophobe renal cell carcinoma (RCC). However, interrater variability has been reported, and the whole-slide histopathology images likely contain underutilized biological signals predictive of genomic profiles.
Experimental design: To address this knowledge gap, we obtained whole-slide histopathology images and demographic, genomic, and clinical data from The Cancer Genome Atlas, the Clinical Proteomic Tumor Analysis Consortium, and Brigham and Women's Hospital (Boston, MA) to develop computational methods for integrating data analyses. Leveraging these large and diverse datasets, we developed fully automated convolutional neural networks to diagnose renal cancers and connect quantitative pathology patterns with patients' genomic profiles and prognoses.
Results: Our deep convolutional neural networks successfully detected malignancy (AUC in the independent validation cohort: 0.964-0.985), diagnosed RCC histologic subtypes (independent validation AUCs of the best models: 0.953-0.993), and predicted stage I ccRCC patients' survival outcomes (log-rank test P = 0.02). Our machine learning approaches further identified histopathology image features indicative of copy-number alterations (AUC > 0.7 in multiple genes in patients with ccRCC) and tumor mutation burden.
Conclusions: Our results suggest that convolutional neural networks can extract histologic signals predictive of patients' diagnoses, prognoses, and genomic variations of clinical importance. Our approaches can systematically identify previously unknown relations among diverse data modalities.
©2021 American Association for Cancer Research.
Similar articles
- Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis.
Cui Y, Zhou Z, Chai Y, Zhang Y. Cui Y, et al. J Immunol Res. 2021 Dec 16;2021:7753553. doi: 10.1155/2021/7753553. eCollection 2021. J Immunol Res. 2021. PMID: 34957313 Free PMC article. - MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R, Khella HW, Scorilas A, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM. Nofech-Mozes R, et al. Cancer Med. 2016 Apr;5(4):656-64. doi: 10.1002/cam4.631. Epub 2016 Feb 10. Cancer Med. 2016. PMID: 26860079 Free PMC article. - A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
Xing Q, Zeng T, Liu S, Cheng H, Ma L, Wang Y. Xing Q, et al. BMC Cancer. 2021 Apr 9;21(1):381. doi: 10.1186/s12885-021-08111-0. BMC Cancer. 2021. PMID: 33836688 Free PMC article. - Management of Atypical Renal Cell Carcinomas.
Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao CK. Liaw BC, et al. Curr Treat Options Oncol. 2017 Sep 14;18(10):61. doi: 10.1007/s11864-017-0501-1. Curr Treat Options Oncol. 2017. PMID: 28913767 Review. - Clinical Application of Digital and Computational Pathology in Renal Cell Carcinoma: A Systematic Review.
Khene ZE, Kammerer-Jacquet SF, Bigot P, Rabilloud N, Albiges L, Margulis V, De Crevoisier R, Acosta O, Rioux-Leclercq N, Lotan Y, Rouprêt M, Bensalah K. Khene ZE, et al. Eur Urol Oncol. 2024 Jun;7(3):401-411. doi: 10.1016/j.euo.2023.10.018. Epub 2023 Nov 3. Eur Urol Oncol. 2024. PMID: 37925349 Review.
Cited by
- Diagnostic accuracy of deep learning in detection and prognostication of renal cell carcinoma: a systematic review and meta-analysis.
Chandramohan D, Garapati HN, Nangia U, Simhadri PK, Lapsiwala B, Jena NK, Singh P. Chandramohan D, et al. Front Med (Lausanne). 2024 Sep 5;11:1447057. doi: 10.3389/fmed.2024.1447057. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39301494 Free PMC article. - A pathology foundation model for cancer diagnosis and prognosis prediction.
Wang X, Zhao J, Marostica E, Yuan W, Jin J, Zhang J, Li R, Tang H, Wang K, Li Y, Wang F, Peng Y, Zhu J, Zhang J, Jackson CR, Zhang J, Dillon D, Lin NU, Sholl L, Denize T, Meredith D, Ligon KL, Signoretti S, Ogino S, Golden JA, Nasrallah MP, Han X, Yang S, Yu KH. Wang X, et al. Nature. 2024 Sep 4. doi: 10.1038/s41586-024-07894-z. Online ahead of print. Nature. 2024. PMID: 39232164 - Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning.
Zheng Q, Wang X, Yang R, Fan J, Yuan J, Liu X, Wang L, Xiao Z, Chen Z. Zheng Q, et al. Cancer Med. 2024 Aug;13(16):e70112. doi: 10.1002/cam4.70112. Cancer Med. 2024. PMID: 39166457 Free PMC article. - Comparing multi-class classifier performance by multi-class ROC analysis: A nonparametric approach.
Xu J. Xu J. Neurocomputing (Amst). 2024 May 28;583:127520. doi: 10.1016/j.neucom.2024.127520. Epub 2024 Mar 6. Neurocomputing (Amst). 2024. PMID: 38645687 - Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma.
Chen S, Song D, Chen L, Guo T, Jiang B, Liu A, Pan X, Wang T, Tang H, Chen G, Xue Z, Wang X, Zhang N, Zheng J. Chen S, et al. Precis Clin Med. 2023 Aug 17;6(3):pbad019. doi: 10.1093/pcmedi/pbad019. eCollection 2023 Sep. Precis Clin Med. 2023. PMID: 38025974 Free PMC article.
References
- Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
- Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults: updated classification of renal tumors. Int J Urol. 2009;16:432–43.
- Linehan WM, Marston Linehan W, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.
- Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22:2089–100.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous